Tango Therapeutics (TNGX) closed at $22.72 on October 30, 2026, up 0.8% from the previous close, on volume of 5,166,340 shares (30-day average 4,148,111).
Data as of October 30, 2026.
30-Oct-2026
Globe Newswire (Fri, 23-Oct 6:30 AM ET)
Globe Newswire (Fri, 16-Oct 7:00 AM ET)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Globe Newswire (Tue, 1-Sep 7:00 AM ET)
Globe Newswire (Tue, 11-Aug 11:00 AM ET)
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Globe Newswire (Tue, 11-Aug 7:00 AM ET)
Tango Therapeutics Announces Executive Chair Transition
Globe Newswire (Thu, 6-Aug 6:24 PM ET)
Tango Therapeutics Issues Major Inducement Equity Grants at Key Inflection Point
Market Chameleon (Mon, 8-Jun 6:30 AM ET)
Market Chameleon (Mon, 8-Jun 3:30 AM ET)
Strong Cash Position and Pipeline Advances Define Tango Therapeutics’ Q1 2026 Update
Market Chameleon (Thu, 14-May 7:24 AM ET)
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Tango Therapeutics trades on the NASDAQ stock market under the symbol TNGX.
As of October 30, 2026, TNGX stock price climbed to $22.72 with 5,166,340 million shares trading.
TNGX has a beta of 0.50, meaning it tends to be less sensitive to market movements. TNGX has a correlation of 0.00 to the broad based SPY ETF.
TNGX has a market cap of $3.83 billion. This is considered a Mid Cap stock.
Last quarter Tango Therapeutics reported $0 in Revenue and -$.37 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.05.
In the last 3 years, TNGX traded as high as $34.39 and as low as $1.03.
The top ETF exchange traded funds that TNGX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
TNGX has outperformed the market in the last year with a price return of +185.1% while the SPY ETF gained +12.3%. However, in the short term, TNGX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -17.6% vs +2.1% return in SPY. But in the last 2 weeks, TNGX shares have fared better than the market returning +3.1% compared to SPY -1.0%.
TNGX support price is $21.35 and resistance is $23.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TNGX shares will trade within this expected range on the day.
